A new study in the journal Chest determined that a structured prescreening counseling and shared decision-making visit with healthcare professionals leads to a better understanding of the benefits and risks of low-dose computed tomography (CT) lung cancer screening. The study found this also improved understanding of the eligibility criteria.

The U.S. Food and Drug Administration (FDA) has cleared the Artis pheno robotic C-arm angiography system from Siemens Healthineers created for use in minimally invasive interventional procedures.

International medical imaging IT and cybersecurity company Sectra has signed a ten-year contract with Isala Hospital, in the Netherlands. The contract comprises Sectra’s information technology (IT) solution for reviewing diagnostic images. The solution enables physicians at Isala Hospital to access and review medical images from any of its two hospitals, regardless of where current and prior images were taken. The joint solution also enables the two sites to efficiently share resources.

The Society of Interventional Radiology (SIR) presented its highest honor, the SIR Gold Medal, to three individuals during its 2017 Annual Scientific Meeting, March 4-9 in Washington, D.C. These awards acknowledge distinguished and extraordinary service to SIR or to the discipline of interventional radiology.

Noninvasive computed tomography (CT) angiography and stress tests can help predict which patients are likely to suffer a heart attack or other adverse cardiovascular event, according to a new study appearing online in the journal Radiology.

March 14, 2017 — Over half of older women with early stage breast cancer received more radiation therapy than what might be medically necessary, adding additional treatment and healthcare costs, according to a study led by Duke Cancer Institute researchers.

Hologic Inc. highlighted its portfolio of innovative breast cancer screening and interventional products, including new solutions for biopsy workflow, at the European Congress of Radiology (ECR) in Vienna, Austria, March 1-5. The company also hosted a symposium and several educational workshops throughout the show, giving attendees opportunities to experience screening and interventional products that offer unique patient and user benefits and address workflow challenges.

FDG positron emission tomography/computed tomography (PET/CT) is a valuable imaging tool for treatment assessment of patients with lung cancer, though systematic evidence for its comparative effectiveness with conventional imaging, such as chest CT, is still evolving, according to a new study.

Stratasys Ltd. announced last week enrollment is now open for 3DHEART, an investigator-initiated trial. 3DHEART, which stands for 3D Hearts Enabling A Randomized Trial, is a randomized, single-blind clinical trial to study the use of patient-specific 3-D-printed models in pre-operative planning for pediatric heart surgery. Stratasys is providing in-kind support with printing of the models to be used in the trial.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now